FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Olds Donald
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/1/2020 

3. Issuer Name and Ticker or Trading Symbol

Acasti Pharma Inc. [ACST]
(Last)        (First)        (Middle)

545 PROMENADE DU CENTROPOLIS, SUITE 100
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

LAVAL, A8 H7T 0A3      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Shares 38000 I Ofra Aslan (Spouse) (6)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)  (1)7/2/2028 Common Shares 50000 $0.77 (5)D  
Share Option (Right to Buy)  (2)4/15/2029 Common Shares 11800 $1.28 (5)D  
Share Option (Right to Buy)  (3)4/15/2029 Common Shares 40400 $1.28 (5)D  
Share Option (Right to Buy)  (4)3/31/2030 Common Shares 86000 $0.53 (5)D  

Explanation of Responses:
(1) Represents 50,000 common shares underlying 50,000 share options granted on July 2, 2018. These share options vested in 6 equal installments on a quarterly basis starting from July 2, 2018 until January 2, 2020.
(2) Represents 11,800 common shares underlying 11,800 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020.
(3) Represents 40,400 common shares underlying 40,400 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020.
(4) Represents 86,000 common shares underlying 86,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a monthly basis starting from March 31, 2020 until March 31, 2021.
(5) Canadian dollars.
(6) 38,000 common shares held by Mr. Olds' wife, Ofra Aslan. Mr. Olds disclaims beneficial ownership of the common shares held by his wife and this report shall not be deemed an admission that Mr. Olds is a beneficial owner of such for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Olds Donald
545 PROMENADE DU CENTROPOLIS
SUITE 100
LAVAL, A8 H7T 0A3
X



Signatures
/s/ Kelsey Weiner, Attorney-in-Fact4/1/2020
**Signature of Reporting PersonDate

Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Acasti Pharma Charts.
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Acasti Pharma Charts.